// App-Quantinova.ai

2117 : Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies

Researchers

Presenter

  • Philip J Mease

Principal Investigators

  • Laura Coates

  • Robert Landewé

  • Iain B McInnes

  • Christopher Ritchlin

  • Tatsuya Atsumi

  • Frank Behrens

  • Dafna Gladman

  • Laure Gossec

  • Peter Nash

  • Barbara Ink

  • Deepak Assudani

  • Rajan Bajracharya

  • Jason Coarse

  • Adam R Prickett

  • Alice Gottlieb

Medical Centers

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • Amsterdam University Medical Center, Overveen, Netherlands

  • Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY

  • Hokkaido University Hospital, Sapporo, Japan

  • Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany

  • Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada

  • Sorbonne Universites, Paris, France

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, NC, USA, Raleigh, NC

  • UCB Pharma, Brussels, Belgium

  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

Locations

  • United States

  • United Kingdom

  • Netherlands

  • Japan

  • Germany

  • Canada

  • France

  • Australia

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • Malondialdehyde

  • Tumor necrosis factor

Drug/Treatment

  • bimekizumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT03895203

  • NCT03896581

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved